预约演示
更新于：2025-12-01
Phenylephrine Hydrochloride
盐酸去氧肾上腺素
更新于：2025-12-01
概要
基本信息
简介苯肾上腺素是一种小分子药物，其作用为α-1肾上腺素能受体激动剂。它主要用于扩张眼瞳以进行眼科检查和手术。通过与虹膜扩张肌中的α-1肾上腺素受体结合，苯肾上腺素盐酸盐引起肌肉收缩，导致瞳孔扩张。这种药物通常用于眼科诊断，例如检查视网膜或测量眼内压。苯肾上腺素盐酸盐以滴眼剂的形式局部给药，通常在10到20分钟内起效，扩张效果可持续数小时 |
药物类型 小分子化药 |
别名 (-)-m-hydroxy-α-(methylaminomethyl)benzyl alcohol、fenilefrine、l-(3-Hydroxyphenyl)-N-methylethanolamine + [22] |
靶点 |
作用方式 激动剂 |
作用机制 ADRA1激动剂(肾上腺素能受体α-1家族激动剂) |
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (欧盟) |
登录后查看时间轴
结构/序列
分子式C9H14ClNO2 |
InChIKeyOCYSGIYOVXAGKQ-FVGYRXGTSA-N |
CAS号61-76-7 |
关联
380
项与 盐酸去氧肾上腺素 相关的临床试验ChiCTR2500112255
Effects of vasoactive drug use on maternal and neonatal outcomes after spinal anesthesia for cesarean delivery when guided by both real-time heart rate and systolic blood pressure.
CTIS2024-517456-35-00
Pharmacodynamics of IMP 08P2002F0 (Fixed dose combination of 0.34% tropicamide and 2.5% phenylephrine hydrochloride, eye drop, Solution) a new ophthalmic mydriatic solution in healthy volunteers.
ChiCTR2500110434
Impact of Intraoperative Norepinephrine versus Phenylephrine Infusion on Postoperative Delirium in Geriatric Hip Fracture Surgery: A Randomized Controlled Trial
100 项与 盐酸去氧肾上腺素 相关的临床结果
登录后查看更多信息
100 项与 盐酸去氧肾上腺素 相关的转化医学
登录后查看更多信息
100 项与 盐酸去氧肾上腺素 相关的专利（医药）
登录后查看更多信息
19,985
项与 盐酸去氧肾上腺素 相关的文献（医药）2026-02-01JOURNAL OF CRITICAL CARE
Effectiveness of prophylactic push-dose vasopressors for preventing arterial hypotension during elective orotracheal intubation: A systematic review and meta-analysis
Review
作者: da Silveira, Fernando ; Nedel, Wagner ; Lisboa, Thiago Costa ; de Oliveira, Luiz Henrique
BACKGROUND:
Orotracheal intubation is frequently associated with arterial hypotension, particularly during induction with agents such as propofol. The use of prophylactic push-dose vasopressors (Push-Dose Pressor - PDP) has been proposed to mitigate this drop in blood pressure. However, the effectiveness of PDPs remains uncertain.
METHODS:
We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) assessing the use of PDPs (epinephrine, ephedrine, phenylephrine, or metaraminol) during sedation for tracheal intubation in adult normotensive patients. Searches were performed in MEDLINE, Embase, and Cochrane Library from inception to September 2024. The primary outcome was the difference in mean arterial pressure (MAP) and systolic blood pressure (SBP) before and after intubation between patients who received PDPs and those who did not. Data were synthesized using an inverse variance method, with heterogeneity assessed using Cochran's Q and I2.
RESULTS:
Twenty-four RCTs involving 1915 patients were included. Most trials were conducted in operating rooms among ASA I-II patients undergoing elective procedures. PDP administration resulted in higher MAP (mean difference: 7.6 mmHg; 95 % CI: 4.3-10.8; I2 = 82 %) and SBP (mean difference: 12.5 mmHg; 95 % CI: 6.4-18.5; I2 = 92 %) compared with controls. Sensitivity analyses excluding phenylephrine or stratifying ephedrine doses yielded consistent findings. Overall certainty of evidence was low due to heterogeneity and indirectness.
CONCLUSIONS:
Prophylactic push-dose vasopressors modestly increase arterial pressure during tracheal intubation in elective surgical patients. Given the low certainty of evidence and limited generalizability, routine use cannot be currently recommended.
2026-01-01Ophthalmology science
Assessing the Impact of Pharmacological Pupil Dilation on Anterior Chamber Cells Counting Using OCT
作者: Chisari, Domenico ; Invernizzi, Alessandro ; Oldani, Marta ; Zicarelli, Federico ; Manni, Priscilla ; Airaldi, Matteo ; Romano, Francesco ; Zaffalon, Chiara ; Barbieri, Lucrezia ; Cimino, Luca
Purpose:
Anterior chamber (AC) cells are seen as hyperreflective dots (HRDs) on anterior segment OCT (AS-OCT), but many factors can affect their objective counting. The aim of this study was to evaluate the effect of pharmacological dilation with tropicamide 0.5% (T) or phenylephrine 2.5% + tropicamide 0.5% (PH + T) on the assessment of AC HRDs density measured in healthy eyes by AS-OCT.
Design:
Cross-sectional, observational study.
Participants:
Healthy subjects with no history of uveitis, no ocular or systemic conditions, and no recent ocular surgery.
Methods:
Participants underwent comprehensive ophthalmic examinations, including single-line AS-OCT (16.5 mm; μm:pixel ratio = 8.79; Anterion, Heidelberg Engineering) imaging before (miosis) and after pupil dilation with either T or PH + T drops. Hyperreflective dots were quantified using FIJI (National Institutes of Health, Bethesda) through the Analyze Particles tool after image binarization. Hyperreflective dot density was calculated by dividing the total HRDs by the AC area and expressed as the number per 10 000 pixels². Iris displacement after dilation was measured using the apex-to-pupil distance (APD).
Main Outcome Measures:
Anterior chamber HRDs density before and after dilation measured by AS-OCT. A generalized Poisson mixed-effects model was used to evaluate the effects of group (miosis, T, PH + T), lens status (phakic, pseudophakic), and their interaction on HRD density. Covariates included age, sex, iris color, and variation in APD after dilation (APDD).
Results:
A total of 100 eyes from 59 healthy participants (55.9% female), mean age 73.0 ± 11.7 years were included. Mean (standard deviation) HRDs density (per 10 000 pixels²) significantly increased from 0.79 (1.44) in normal photopic conditions to 1.71 (3.30) after the dilatation in the T group and from 0.52 (0.83) to 15.8 (25.8) in the PH + T group (P < 0.001). Dilation with T (P = 0.03) or PH + T (P < 0.001), increased APDD (P < 0.001), and the interaction between PH + T and phakic status (P < 0.001) were all significantly associated with higher HRDs density.
Conclusions:
Pharmacological dilation, especially with PH + T, significantly increases HRDs in the AC of healthy subjects, with a more pronounced effect in phakic eyes and greater APDD. These findings suggest increased iris-lens friction and potential pigment release after dilation, providing critical considerations for standardizing AS-OCT-based assessments of AC inflammation.
Financial Disclosures:
The author has no/the authors have no proprietary or commercial interest in any materials discussed in this article.
2026-01-01BIOCHEMICAL PHARMACOLOGY
Melatonin protects vascular homeostasis by restoring PVAT redox balance in arterial hypertension
作者: Peixoto, Ana Laura S. ; Lobato, Núbia S. ; Nogueira, Thyêssa G.S. ; Santos, Ana Carolina M.A. ; Alves, Juliano V. ; Cunha, Rosana G.A. ; Costa, Rafael M. ; de Lima, Júlia F. ; Coelho, Lauren S.
Perivascular adipose tissue (PVAT) exerts vasoprotective role by releasing factors that modulate vascular tone. In arterial hypertension (AH), PVAT undergoes phenotypic alterations characterized by increased oxidative stress, inflammation, and loss of anticontractile function. Melatonin is a pleiotropic molecule with antioxidant and anti-inflammatory properties. This study investigated whether melatonin restores PVAT function and improves vascular reactivity in spontaneously hypertensive rats (SHR). Wistar and SHR rats were treated with vehicle or melatonin (5 mg/kg/day, orally) for 14 days. Vascular reactivity was assessed in aortic rings with and without PVAT in response to phenylephrine and acetylcholine. Reactive oxygen species (ROS) generation, hydrogen peroxide levels, nitric oxide (NO) bioavailability, expression and activity of antioxidant enzymes, and inflammatory cytokines were measured in PVAT. WT1 brown adipocytes were stimulated with angiotensin II in the presence or absence of melatonin to evaluate redox-related gene expression and oxidative stress markers. SHR PVAT exhibited loss of anticontractile function and impaired endothelium-dependent relaxation, associated with elevated ROS and hydrogen peroxide production, reduced NO levels, and increased NOX-1 expression. Catalase activity and NO bioavailability were decreased, whereas pro-inflammatory cytokines were upregulated. Melatonin treatment restored the anticontractile effect of PVAT, improved acetylcholine-induced relaxation, reduced oxidative stress, restored catalase activity, and preserved NO levels. In vitro, melatonin prevented angiotensin II-induced ROS generation, NOX-1 upregulation, and catalase downregulation in adipocytes. Melatonin restores PVAT function and vascular reactivity in AH by reducing oxidative stress, preserving antioxidant enzyme activity, and improving NO bioavailability. Melatonin shows potential to reverse PVAT dysfunction in AH.
100 项与 盐酸去氧肾上腺素 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 麻醉 | 美国 | 2019-10-21 | |
| 瞳孔散大 | 美国 | 2013-03-21 | |
| 低血压 | 日本 | 1954-10-11 | |
| 休克 | 日本 | 1954-10-11 | |
| 心动过速 | 日本 | 1954-10-11 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 大便失禁 | 临床3期 | 英国 | 2007-02-01 | |
| 血管迷走神经性晕厥 | 临床2期 | 美国 | 2021-07-20 | |
| 血液肿瘤 | 临床2期 | 美国 | 2015-05-14 | |
| 放射性口腔黏膜炎 | 临床2期 | 美国 | 2015-05-14 | |
| 尿失禁 | 临床2期 | 以色列 | 2009-09-01 | |
| 生理性性功能障碍 | 临床1期 | 美国 | 2018-07-09 | |
| 心理性性功能障碍 | 临床1期 | 美国 | 2018-07-09 | |
| 粘膜炎 | 临床1期 | 美国 | 2010-03-01 | |
| 口腔炎 | 临床1期 | 美国 | 2010-03-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 60 | 鑰鹹顧餘構製窪艱簾製(鏇積觸鑰網夢艱廠憲淵) = 鹹鹽顧願餘獵顧鏇獵繭 糧網夢廠糧壓艱獵醖憲 (網鬱膚觸積網窪築憲鹽, 0.07 ~ 0.08) | 积极 | 2025-11-01 | ||
鑰鹹顧餘構製窪艱簾製(鏇積觸鑰網夢艱廠憲淵) = 襯衊顧簾製鹹範襯憲範 糧網夢廠糧壓艱獵醖憲 (網鬱膚觸積網窪築憲鹽, 0.85 ~ 0.95) | |||||||
临床4期 | 18 | 窪蓋廠鏇顧壓鹽製積顧(醖範膚願衊淵獵鹹願襯) = 範遞夢繭顧餘願鹽選壓 選築醖襯獵願窪齋鬱糧 (醖選簾艱簾齋糧夢網網, 0.91) 更多 | - | 2025-08-22 | |||
EURETINA2024 人工标引  | N/A | - | 53 | 膚糧觸構網鑰鏇憲獵鹹(簾襯膚窪選積簾鑰鹽膚) = 憲鹹觸壓網網獵鏇淵壓 觸鏇築獵憲遞衊衊夢遞 (衊簾獵築願糧鏇餘鹹顧 ) 更多 | 积极 | 2024-09-19 | |
临床2期 | 143 | 餘襯廠廠廠選廠淵繭壓(範鹹願憲選糧鹹遞醖膚) = 衊獵壓鹽壓獵選窪餘艱 廠鬱壓鹹鏇製鏇夢遞網 (糧鏇憲壓窪壓構餘齋鬱, 1.05) 更多 | - | 2024-06-24 | |||
临床4期 | - | Phenylephrine infusion | 鏇鏇範繭淵衊齋襯鑰淵(壓窪範選齋鬱積蓋鏇顧) = 糧觸願築鏇齋製繭顧網 繭築顧淵範選糧衊淵艱 (壓夢築繭繭餘觸範衊簾, 3.6 ~ 5.4) 更多 | - | 2023-08-01 | ||
临床1期 | - | 36 | 鹽淵醖襯廠廠範壓醖淵(窪憲衊獵構製艱襯膚顧) = 壓襯願遞廠製艱繭醖鏇 鹽範襯齋夢願襯網網鏇 (壓壓鑰網遞鹽壓願淵範 ) 更多 | - | 2022-12-08 | ||
临床4期 | 麻醉 维持 | 124 | 願膚鑰鹽壓衊糧鹽鏇齋(顧壓衊淵網膚淵獵壓網): ARD = -2.4 (95% CI, -4.4 ~ -0.5) 更多 | 积极 | 2022-10-24 | ||
临床4期 | 15 | (Phenylephrine) | 衊網夢獵鹽願鏇憲壓憲(憲糧鹽鹽廠夢壓糧範糧) = 糧選獵蓋繭餘積艱憲憲 鹽窪醖衊獵鏇蓋窪範醖 (鑰觸鑰顧膚蓋簾糧憲壓, 0.7) 更多 | - | 2022-08-05 | ||
(Arginine Vasopressin) | 衊網夢獵鹽願鏇憲壓憲(憲糧鹽鹽廠夢壓糧範糧) = 鹽淵襯衊醖醖顧蓋鏇淵 鹽窪醖衊獵鏇蓋窪範醖 (鑰觸鑰顧膚蓋簾糧憲壓, 0.41) 更多 | ||||||
N/A | 110 | (Phenylephrine) | 簾齋壓餘鬱構獵蓋壓膚(衊鑰艱蓋艱積蓋衊壓壓) = 獵觸鹽鏇鹹齋築簾製夢 壓構壓願築範鹽夢築鑰 (繭構網鏇醖淵夢願繭繭, .07) 更多 | - | 2022-06-02 | ||
(Ephedrine) | 簾齋壓餘鬱構獵蓋壓膚(衊鑰艱蓋艱積蓋衊壓壓) = 餘膚鹽鬱窪衊艱顧願齋 壓構壓願築範鹽夢築鑰 (繭構網鏇醖淵夢願繭繭, .1) 更多 | ||||||
临床3期 | - | 鑰壓淵鬱衊遞範衊糧選(蓋淵繭廠淵蓋簾網艱築) = 鬱顧製餘鬱顧衊衊選膚 衊廠積膚衊齋膚齋壓簾 (鹽繭齋窪鬱鏇製獵獵廠 ) | 积极 | 2021-11-13 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用